Motivation: Integration of metabolic networks with '-omics' data has been a subject of recent research in order to better understand the behaviour of such networks with respect to differences between biological and clinical phenotypes. Under the conditions of steady state of the reaction network and the non-negativity of fluxes, metabolic networks can be algebraically decomposed into a set of sub-pathways often referred to as extreme currents (ECs). Our objective is to find the statistical association of such sub-pathways with given clinical outcomes, resulting in a particular instance of a self-contained gene set analysis method. In this direction, we propose a method based on sparse group lasso (SGL) to identify phenotype associated ECs based on gene expression data. SGL selects a sparse set of feature groups and also introduces sparsity within each group. Features in our model are clusters of ECs, and feature groups are defined based on correlations among these features. Results: We apply our method to metabolic networks from KEGG database and study the association of network features to prostate cancer (where the outcome is tumor and normal, respectively) as well as glioblastoma multiforme (where the outcome is survival time). In addition, simulations show the superior performance of our method compared to global test, which is an existing selfcontained gene set analysis method. Availability and implementation: R code (compatible with version 3.2.5) is available from http:// www.abi.bit.uni-bonn.de
Introduction
Metabolic networks are usually represented as a collection of enzyme catalysed biochemical reactions. There are numerous databases with such information (Croft et al., 2011; Kanehisa et al., 2012; Le Novére et al., 2006) . Metabolic networks can be represented as a stoichiometric matrix, where the rows represent compounds of reactions and the columns correspond to reactions. Analysis and simulation of metabolic networks comprises different techniques, such as flux balance analysis and analysis of biologically functioning sub-pathways in steady state. The goal of flux balance analysis is to find a flux vector that satisfies a certain optimality criterion under constraints (e.g. maximal production of a desired substance), whereas analysis of sub-pathways focuses on the topology of a metabolic network. Techniques for sub-pathway analysis comprise extreme currents (ECs) (Clarke, 1988) , elementary flux modes (EFMs) (Schuster et al., 2000) and extreme pathways(EPs) (Bordbar et al., 2014; Schilling et al., 2000) . A comparison between different metabolic sub-pathway decomposition techniques can be found in (Llaneras and Pic o, 2010) . Since the number of possible sub-pathways in EC, EFM and EP analysis can explode in a combinatorial fashion with the size of the overall metabolic network (Klamt and Stelling, 2002) , such an analysis is typically restricted to defined metabolic sub-systems, e.g. canonical pathways.
In short, sub-pathways identified via EFM, EC or EP analysis are basically steady state reaction-flux distributions capturing the wide range of behaviour the network is capable to display. Essentially, these sub-pathways are invariants of the network and hence do not require kinetic rate parameters to be known or estimated, which is often very difficult. In biological systems the function of metabolic networks is regulated by gene and protein expression levels which affect the enzyme concentrations. Therefore, out of many subpathways some may be more associated with a given phenotype than others. Insights into the linking of certain sub-pathways to a clinical phenotype could help development of mechanism based biomarkers (Amadoz et al., 2015) and guide the identification of novel drug targets in the future.
Following this idea we propose a novel method, which takes as an input a metabolic network or canonical pathway together with gene expression data. Based on the given metabolic network we first compute ECs, represent them as gene sets and ask the question which ones are statistically significant associated with given clinical or biological phenotypes based on gene expression data.
Statistical association of gene sets to phenotypes has been studied for a long time in the bioinformatics community. According methods can be broadly divided into 'self-contained' or 'competitive'. A detailed overview can be found in Maciejewski(2014) and Nam and Kim (2008) .
The self-contained approach considers only the genes mapable to a defined pathway of interest while computing the association with the phenotype and disregarding the genes not in that gene set. The null hypothesis in self-contained methods is that no gene in the gene set is associated with the phenotype. A prominent example is the global test (GT) (Goeman et al., 2004) . The GT tries to reject the null hypothesis that all coefficients in a generalized linear model linking gene expression and phenotype are exactly zero.
In competitive methods each gene set of interest is viewed together with the whole universe of existing genes. The most prominent example is the GSEA method (Subramanian et al., 2005) . The null hypothesis in competitive methods is that genes in the given gene set are 'at most as often differentially expressed' between conditions of interest as the genes in the complement of the given gene set.
Existing approaches estimate the association of EFMs with a phenotype based on high-throughout '-omics' data using a hypergeometric test which is a competitive method. In Schwartz et al. (2007) the enrichment of EFMs computed from KEGG pathways are associated with gene expression data in various stress conditions of Saccharomyces cerevisiae. The approach in Rezola et al. (2013) uses a multivariate hypergeometric test to link EFMs in a genome scale human metabolic network to tissue specific gene expression differences in human. This technique was also applied to study metabolic differences between lung cancer subtypes (Rezola et al., 2014) . The methods based on hypergeometric test require a threshold to discretize the genes into two or more classes based on their expression level differences in different biological or clinical outcomes. Therefore, they are sensitive to such a threshold. Moreover, the application of hypergeometric test is limited to discrete phenotypes (e.g. cancer or healthy) and not applicable to continuous clinical outcomes e.g. survival times. Finally, the universe of all genes has to be defined appropriately (Maciejewski, 2014) which could be tricky. A different approach was undertaken by YANA (Schwarz et al., 2005) which uses optimization to minimize the sum of squared error between reaction fluxes in EFMs and the fluxes based on gene or protein expression. A review on existing approaches can be found in Rezola et al. (2015) .
In this article, we propose a method based on a sparse group lasso (SGL) (Simon et al., 2013) to identify phenotype associated ECs based on gene expression data. SGL selects a sparse set of feature groups and also introduces sparsity within each group. Features in our model are clusters of ECs, and feature groups are defined based on correlations among these features. In contrast to other statistical techniques, such as an elastic net (EN) (Zou and Hastie, 2005) , SGL explicitly takes the correlation between features into account. Moreover, SGL specifically suits the application scenario where the number of features exceeds the number of samples.
Our SGL-based approach has similarities to a self-contained gene set test. However, in contrast to other techniques we estimate the probability of a network feature (i.e. EC cluster) to be a predictor of the biological or clinical phenotype. This is done via a bootstrap approach. Using simulations, we show that our method performs better than the GT, which is a self-contained gene set test.
The reason for choosing ECs instead of EFMs or EPs within our approach is to provide the link to well-established techniques from stoichiometric network analysis. For example, ECs have been employed to compute Hopf bifurcations (yielding oscillations) (Errami et al., 2015; Gatermann et al., 2005) and bistability (Aguda and Clarke, 1987) of biochemical reaction networks. However, the method described in this paper can be readily applied to EFMs and EPs as well. Furthermore, splitting reversible reactions into two forward and backward reactions as employed in our approach renders EC and EFM decompositions equivalent (Gagneur and Klamt, 2004) .
The major benefits of our method are four fold: first, we come up with a method to address the typical high overlap of individual ECs because of the network structure as well as correlations at the level of '-omics' data. This issue is addressed by focusing on 'clusters of ECs' to define network features and defining groups (i.e. clusters of network features) in the statistical model based on correlations among these features. Second, our approach is flexible enough to analyse different types of phenotypes e.g. categorical (cancer versus healthy), continuous or censored survival times. Third, our approach does not require a discretization of genes into categories (as required by hypergeometric test). Finally, our method estimates a probability of each network feature to be associated with the phenotype, hence appropriately taking into account the noise in observed data.
In this article, we apply our method to metabolic KEGG models (when these models are available as biochemical reaction networks). ECs then correspond to sub-pathways within a given KEGG model. Although metabolic KEGG pathways are frequently used to analyse and understand human diseases based on gene expression or otheromics data, the reaction network structure of these models is usually ignored. In contrast, our approach relates changes in specific subreaction systems defined as ECs and groups of ECs to observed changes of the phenotype. Importantly, a given KEGG model can have numerous ECs, implying that KEGG models as a whole might not always offer the right granularity to describe and understand a biological mechanism. Additionally, the ECs in a given reaction network can identify feedback loops (Sensse et al., 2006) which are important for dynamics.
This article is organized in three parts. First, we explain our proposed method. Second, we compare it with the well-established GT and EN based on simulated data. Last, we demonstrate the application of our method by studying the deregulation of disease-related KEGG pathways in prostate cancer (where the outcome is tumor and normal, respectively) as well as glioblastoma multiforme (GBM) (where the outcome is survival).
Methods and results

Extreme currents
The dynamics of biochemical reaction networks can be modelled by ordinary differential equations (ODEs) (Horn and Jackson, 1972) . In such an approach, the rate of change of concentration of a chemical species (x) is denoted by _ x and can be represented in a compact form in the following manner:
where N is the stoichiometric matrix consisting of s species and n reactions and v denotes the n dimensional row vector of fluxes. In steady state condition (i.e. _ x ¼ 0), Equation (1) reduces to a system of homogeneous linear equations with unknown v. The steady state solution along with non-negativity constraint on the fluxes can be described as a polyhedron (or flux cone) and is defined as follows:
Reversible reactions are split into separate forward and backward reactions. The vertices of polyhedron P are called ECs (Clarke, 1988) or convex bases which can be understood as sub-pathways in the network. The set of fluxes in steady state are linear combinations of ECs and can be written as
where E is a k Â n EC matrix and j is a k dimensional row vector of positive real numbers called as convex parameters. In literature, such pathways are also referred to as EFMs or EPs, depending on the way in which reversible reactions are split (affecting the nonnegativity constraint on the fluxes). In our case, the ECs, EFMs and EPs are equivalent as the reversible reactions are split into separate forward and backward reactions. If this is not the case then EFMs can be dependent (i.e. some EFMs are non-negative combination of others) (Llaneras and Pic o, 2010) . The ECs were computed using the PoCaB software (Samal et al., 2012) . It should be noted that due to the splitting of reversible reactions spurious cycles appear. So, for every split there appears an EC, which only denotes the forward and backward reaction components of the reversible reaction (Wagner and Urbanczik, 2005) . Therefore, such spurious cycles are filtered out in our approach. The ECs are steady state flux distributions. In order to investigate the ECs with respect to gene expression data, enzymes in the flux carrying reactions need to be mapped to genes. For every EC i.e. row vector of matrix E denoted by E j (Equation 3), a row vector g j , corresponding to the jth EC, is constructed by mapping the flux carrying reactions denoted by f1 i n j E ji 6 ¼ 0g to those genes, which participate in the reactions as enzymes. More specifically, this is done by constructing an ' dimensional indicator vector (where ' n because the mapping from fluxes to genes can be many to one) with as many entries as there are mappable genes in the overall subpathway. Then, entry k 0 in g j is set to 1, if gene k 0 can be mapped to EC E j . Such a mapping can result in duplicates. Therefore, only the distinct vectors g 1 ; . . . ; g m are considered where m denotes the number of gene sets obtained from k ECs and m k is due to the duplicates resulting from the mapping. Finally, the gene set vectors g 1 ; . . . ; g m can be joined into a m Â ' matrix G. The gene-toenzyme-to-reaction mapping may also be represented via Boolean logic in certain non-trivial cases, e.g. alternative splicing (c.f. Schellenberger et al., 2010) . In this article we do not consider such Boolean rules or, more generally, Boolean Networks describing the association of genes and proteins to reactions (Schellenberger et al., 2010) . We would like to mention that the analysis of such Boolean Networks could also involve topology based techniques in the spirit of EFMs (Wang and Albert, 2011) , which opens the chance to extend our method accordingly in the future.
Computation of network features
Let us define gene set corresponding to g j as the support of g j : supp
e. the non-zero entries in row vector G j ). For matrix G, let S be set of ECs represented as gene sets. The ECs having empty gene sets are excluded from S. In practice, the gene sets are often highly overlapping or even identical. The issue of identical gene sets is already addressed in the previous section. Therefore, individual ECs and associated gene sets, respectively, will be hard to discriminate based on gene expression data. To address this issue we grouped gene sets in S into clusters.
Let us denote S 0 as the partition of S such that S 0 breaks S into subsets denoted as S 0 ¼ fS (Jain and Dubes, 1988 ). Here we used agglomerative hierarchical clustering (Maechler et al., 2016) as a widely accepted technique for cluster analysis. Agglomorative hierarchical clustering works by successively joining data points (which are gene sets i.e. elements in S) based on a defined similarity measure, resulting in a tree like structure (dendrogram), which represents similarities of groups of data points (in this case gene sets) in a hierarchical manner. In our case we employed the Jaccard index as similarity measure between gene sets and the complete linkage strategy to join clusters. A grouping is then found by prescribing a certain number of clusters and cutting the dendrogram at the corresponding height. Here the number of clusters m 0 is selected by computing the silhouette index (Rousseeuw, 1987) , which is an established approach to estimate the quality of a clustering. For this purpose we varied the number of clusters from 2 to m 0 À 1 and selected the optimal number of clusters according to the maximum silhouette index. The network feature corresponding to S 0 l ; 1 l m 0 is then computed by taking the union of the gene sets in S 0 l . These network features are used in the subsequent steps to fit the linear model.
Combining network features with gene expression data and phenotypes
The idea behind our approach is to combine gene expression data, phenotypes and metabolic network features. Gene expression data of our interest is generally represented in form of a l Â q matrix D, where rows represent those genes which map to the pathway of our interest and columns represent biological or patient samples. The biological or clinical phenotype is given by a q-dimensional vector y.
Entries in y could be categorical (e.g. cancer or healthy) or continuous real numbers (e.g. a patient's quantitative response to a certain treatment).
First, we construct a q Â m 0 feature matrix X (recall m 0 is the number of clusters as defined in the previous section) as: 
Estimating the influence of network features on the phenotype via SGL
Modelling categorical and continuous phenotypes
We assume phenotype y to be linked to feature matrix X via a generalized linear model
where the measurement noise and f a link function, e.g. logit in case of categorical phenotypes and the identity function in case of continuous phenotypes (McCullagh and Nelder, 1989) . Importantly, we suppose b to be a sparse vector, i.e. most coefficients are zero. That means the phenotype is determined by a sparse combination of network features, which we aim to identify from expression data and observed phenotypes. This addresses the nonidentifiability issue arising in high dimensional setting where number of features is greater than number of samples. Another complicating factor in our context is that the gene expression data typically exhibits a non-trivial correlation structure that may not coincide with network features. For example, certain groups of genes might be activated or deactivated by common regulatory elements, resulting in a block-like correlation matrix. In order to address this type of correlation, we assign network features to groups. Groups should be assigned in such a manner that the distance between the features inside the group (intra-group) should be small whereas the distance to features of other group (inter-group) features should be high. This is done by hierarchical average clustering of network features based on gene expression data where the distance between two features S (5) under the above described restrictions, namely sparsity and organization of network features into correlated groups, can be fitted via a SGL (Simon et al., 2013) . The SGL solves the following optimization problem:
where q is the dimension of the response vector y, X l ð Þ is the submatrix of X with columns corresponding to the predictors in group l, b l ð Þ is the coefficient vector of that group and p l is the length of b l ð Þ and k a the tuning parameter controlling the sparsity of coefficient vector b: Larger k implies more sparsity, but less precise fit to the data. Moreover, a 2 0; 1 ½ is a parameter that balances between sparse selection of whole feature groups and sparse selection within each feature group. For the extreme case a ¼ 0 we recover the group lasso (Yuan and Lin, 2006) , which only performs selection of feature groups of a whole. For a ¼ 1 we arrive at the original lasso model (Tibshirani, 1996) , which selects features independent of any group structure.
In practice k and a are tuning parameters. These are usually estimated via 5-fold cross-validation: Data are split into five distinct sets (¼ folds), and the SGL model is trained on 4 folds while leaving out the rest for testing. We then record the prediction error made by the model on the test set. The whole procedure is successively repeated until each fold has been left out once for testing. The average prediction error made during the cross-validation procedure can be used as a quality measure for the SGL model, which can be recorded over a grid of k and a parameters. Accordingly, a good combination of these parameters can be selected. (Zou and Hastie, 2005) is the explicit handling of the feature correlation structure.
Patient survival outcomes
Our approach can also be employed for associating network features with patient survival: In case of patient survival data y ¼ f t i ; d i ð Þji ¼ 1; . . . ; qg where t i is the observed survival time of patient i and d i 2 f0; 1g indicates the censoring status. Instead of a generalized linear a Cox proportional hazard model is assumed, i.e.:
where f tjX ð Þ is the hazard at time t and f 0 t ð Þ the baseline hazard. See McCullagh and Nelder (1989) for an overview about survival models. Notably, the SGL can also be employed to fit this type of model.
Bootstrapping
In order to quantify the uncertainty associated with selection of a particular feature we employ a bootstrap test. The uncertainty with respect to the relevance of a particular feature is measured by the probability that a particular feature is associated to the phenotype. The test is performed by randomly sampling the rows in X and the corresponding entries in y (with replacement) and re-estimating coefficients of the SGL model. This is repeated a number of times (100 times during the simulations and 500 times for real data), and the fraction of times in which a coefficient is non-zero, gives the probability for the association of a specific feature with the phenotype. This probability value is denoted as bootstrap frequency.
Results
Metabolic network reconstruction
Metabolic networks, namely Glycolysis / Gluconeogenesis (hsa00010), Steroid hormone biosynthesis (hsa00140), Pyrimidine metabolism (hsa00240), Alanine, aspartate and glutamate metabolism (hsa00250) and Propanoate metabolism (hsa00640), were obtained from KEGG database in KGML format (Kanehisa et al., 2012) . The KGML files were converted to SBML using KEGGtranslator (Wrzodek et al., 2011) .
KEGG reactions are extensively annotated with main reactantproduct pairs called RCLASS (Kanehisa et al., 2012) . For our purpose, we considered only such pairs. A single reaction can have multiple main pairs and in that case we treated each main pair as an independent reaction. We observed that the number of ECs increases substantially by considering only the main pairs. This happens due to the presence of compounds in side pairs (e.g. water, cofactors etc) which may not always be in steady state. The benefits of such a decomposition are analysed in Faust et al. (2009) in the context of searching optimal paths in KEGG networks. Moreover, only main pairs are displayed in the visualization of the pathways on the KEGG website.
Compounds lying at the boundary of the system (i.e. acting as source or sinks) are assumed not to be in steady state condition. Thus, the reaction network for EC computation involves only those species participating in the main reaction pairs and occurring as non-boundary species. In the computation of EFMs these are referred as external metabolites. To identify such compounds we computed the row-sum of stoichiometrix matrix N and discarded those chemical species whose row-sum is non-zero. This means the chemical species whose net production and consumption are not balanced are considered to be external metabolites.
Computation of ECs and feature matrix
We took 77 KEGG metabolic models, computed the ECs and also the network features using the steps described in Section 2. Supplementary Figure S1 depicts the empirical run time for the EC decomposition as a function of number of reactions per metabolic network model, indicating a run time of below 1 s for the largest KEGG model with almost 180 reactions. Moreover, the running times among all the selected models did not exceed 5 s. However, the growth of running times of the algorithm with respect to the number of reactions appears to be near exponential (cf. Supplementary Fig. S1 ), thereby limiting its ability to determine the ECs of large genome scale models. Calculations were performed on an Intel Xeon E5-2697 v2 CPU with 2.7 GHz.
Mapping ECs to gene sets and clustering them to generate network features results in considerable reduction in the number of features. We plot this analysis as log of ratio of the number of features compared to the number of original ECs. This is shown in Supplementary Figure S2 . Essentially, a large number of ECs in flux space often map to few features defined by gene sets. 71 models have number of features less than the number of ECs whereas 6 models have exactly equal number of features to the number of ECs.
Simulations
A certain proportion of network features were declared as relevant, denoted by set F and the remaining set of features were denoted by set F 0 . The response variables (i.e. censored survival times or categorical phenotypes) were generated from F. A similar approach for simulations was followed in Simon et al. (2013) . A SGL penalized Cox regression model for censored survival times and SGL penalized logistic regression for categorical phenotypes was fitted to the data to identify the relevant features. The performance of SGL was compared with GT and EN based on the area under the curve (AUC) values measuring the performance of a binary classifier computed using the pROC package in R (Robin et al., 2011) . The details of the simulations are described in Supplementary Material section "Simulations". Simulation results for censored survival times as response variables are shown in Table 1 and Supplementary Tables S5-S8 and for categorical phenotypes as response variables are shown in Table 2 and Supplementary Tables S9-S12. In both the scenarios, a clear overall benefit of our SGL could be observed, reflected by a statistically significant improvement of our proposed method compared to the GT and EN in the vast majority of simulation settings, which increased with the number of samples in the dataset. The statistical significance was estimated based on a Wilcoxon signed rank tests. Notably, different reconstructed metabolic networks were tested in our simulation, which differed in their number of extractable network features. It was observable that in simulation cases, where the number of network features far exceeded the number of samples in the dataset the performances of both compared methods were comparably low and equal, whereas in all other cases our SGL method could benefit significantly more than GT and EN. Our employed EN implementation (R-package glmnet) in several cases resulted into an error message, hence Tables 1 and 2 and in Interestingly with increasing number of relevant features we saw a decrease in the performance of GT, EN and SGL. This is most likely due to the increasing number of correlated relevant features, resulting in non-identifiability of the individual network features.
Application to real data
To evaluate our proposed method on real data we selected metabolic KEGG pathways from literature which had been reported to be deregulated in prostate cancer and GBM. Thereafter, we used gene expression data to compute the relevant network features in these networks based on our method.
Prostate cancer
A comprehensive analysis of pathways in prostate cancer was reported in (Sreekumar et al., 2009) where metabolomic profiles were found to be differentially expressed in benign prostate, clinically localized prostate cancer and metastatic disease. More specifically, Sarcosine was found to be highly elevated in tumor samples.
Data source
Sarcosine can be found in the glycine, serine and threonine KEGG pathway (KEGG ID: hsa00260). We mapped normalized gene expression data from Brase et al. (2011) , comprising 47 prostate tumor tissue samples along with 48 normal prostate tissue samples (GSE29079, Affymetrix Human Exon 1.0 ST).
Computation of ECs and integration of expression data
Application of EC decomposition and network feature extraction to hsa00260 resulted into 10 features. After mapping of gene expression data the SGL-based logistic regression model was fitted. The number of permutations in the bootstrap test was fixed at 500. A short summary of obtained results is provided in Supplementary  Table S1 .
Results
The histogram of bootstrap frequencies is shown in Supplementary  Figure S4 . A further overview is provided in Supplementary Tables S1 and S2. A gap is observable in the histogram between the bins 0.6-0.7 and 0.8-0.9. Therefore, we chose a confidence cut-off value of 0.8 resulting in 5 features as relevant out of 10. Upon investigation, out of these five features, two features included glycine-Nmethyltransferase (GNMT) (Fig. 2) . GNMT has been associated with elevated Sarcosine levels (Sreekumar et al., 2009 ) and prostate cancer progression in general (Song et al., 2011) . As visualized in Figure 2 (left) Sarcosine can be converted into Methanal (formaldehyde) via Sarcosine Dehydrogenase (SARDH). Additionally, through a different mechanism Dimethylglycine can be converted to Methanal (formaldehyde) via Dimethylglycine Dehydrogenase (DMGDH). It has been reported that prostate cancer patients show increased formaldehyde concentrations in their urine ( Span el et al., 1999) . Both the ECs differ by the presence of a single enzyme Avg refers to median value of AUC values obtained in 50 simulation runs. P-values refer to the null hypothesis of no difference between GT, EN and SGL. NA refers to the failure of EN method (at least in one of the iterations). NA* refers to the inability to compute the P-value due to identical AUC values of the two methods. Avg refers to median value of AUC values obtained in 50 simulation runs. P-values refer to the null hypothesis of no difference between GT, EN and SGL. NA refers to the failure of EN method (at least in one of the iterations).
namely, SARDH. This also explains their occurrence in a single cluster associated to network feature id 5.
The right most EC in Figure 2 shows the reversible reaction of Sarcosine to Glycine, where the forward and backward components are catalysed by different enzymes.
Glioblastoma multiforme
In Wolf et al. (2010) , the authors discuss the role of nucleotide metabolism in GBM. Based on that we decided to investigate pyrimidine metabolism in more depth, which is a sub-category of nucleotide metabolism.
Data source
Normalized expression profiles from 342 patients were downloaded and combined from The Cancer Genome Atlas (TCGA) database (McLendon et al, 2008 ) (HG-U133A Affymetrix Array platform). To correct for possible batch effects we applied the ComBat method (Johnson et al., 2007) . Expression data were mapped to the pyrimidine metabolism KEGG pathway (ID: hsa00240). In addition to gene expression clinical data were retreived from TCGA. The median, minimum and maximum survival times were 357, 26 and 3880 days, respectively. 27.19% of the patients had censored outcomes.
Computation of ECs and integration of expression data
Application of EC decomposition and network feature extraction to hsa00240 resulted into 20 features. After mapping of gene expression data the SGL based Cox regression model was fitted. The bootstrap test was performed in the same way as described before. A short summary of obtained results is provided in Supplementary  Table S3 .
Results
The histogram of bootstrap frequencies is shown in Supplementary  Figure S4 . Unlike the histogram in Supplementary Figure S4 , there is no clear indication of a gap between the bins. Therefore, we consider confidence cut-off values of 0.8 and 0.5, resulting in 7 and 11 features as relevant out of 20 (see Supplementary Table S4 for an overview). It was found that three out of these 11 relevant features contained enzymes previously reported as dysregulated in GBM (Bardot et al., 1994; Wolf et al., 2010) , namely thymidylate synthase, thymidine phosphorylase (TYMP), uridine phosphorylase and ectonucleoside triphosphate diphosphohydrolase 3. Additionally, 1 out of 7 relevant features contained the enzyme TYMP. As seen from Supplementary Figure S5 , TYMP catalyses the reaction from Thymidine to Thymine. Furthermore, the two ECs differ in the reaction route from TTP to dTMP. The other enzymes catalyse several reactions. Our method unravels these multiple reaction routes.
Conclusion
We described a method to associate features (namely reaction subpathways based on ECs) of a metabolic network to clinical or biological phenotypes with the help of gene expression data. Extraction of relevant reaction sub-pathways from a metabolic network has previously found application in drug target identification and network robustness analysis (see Papin et al., 2003 ; for an overview). ECs are invariants of the reaction network structure and enumerate possible network behaviours. However, under real biological conditions not all of these possible behaviours are realized. Gene expression data reflect constraints on concentrations of the enzymes, which regulate the functioning of the metabolic network. Gene expression data can thus be employed to identify, which of the possible network behaviours and reaction sub-pathways, respectively, in reality contribute to a particular biological or clinical phenotype. Notably, our approach demonstrates that this is not only possible in a categorical sense by e.g. discriminating normal from cancer cells, but with respect to more complex clinical outcome measurements, such as censored survival times. However, a major difficulty arising in that context is that gene expression data shows a non-trivial correlation structure, which is not necessarily in agreement with defined network features. Our proposed method uses a SGL-based approach to address this issue. Our simulation studies demonstrated the superiority of this method compared to a conventional GT and to EN. In essence our method combines algebraic analysis of the metabolic network structure with an unbiased view on the transcriptional level. Notably, metabolic networks (such as available in KEGG) are viewed a biochemical reaction systems in our approach, and ECs correspond to sub-systems. Furthermore, such sub-systems are often referred to as reaction routes in the literature (Schuster et al., 2002) .
We demonstrated the application of our SGL method by investigating the role of the metabolite Sarcosine in prostate cancer and pyrimidine metabolism in GBM. In both cases statistically stable identified network features could be linked to findings from the medical literature, supporting the relevance of our method.
We made our proposed approach computationally practical via parallel computing. The computation time for the GBM example was <2 h and for prostate cancer application < 30 min on a AMD Opteron 6380 64 core machine with 512 GB RAM. This was achievable, due to the focus on individual metabolic network models based on prior knowledge about the disease. Of course, the ultimate goal would be a genome-scale analysis of metabolic networks e.g. Recon 2 (Thiele et al., 2013) , which currently is impossible with our method due to the computational complexity of EC computation.
Some constraint-based modelling approaches, e.g. flux balance analysis, allow for integrating genome-scale metabolic networks with experimental data (Becker and Palsson, 2008; Zielinski et al., 2015) . However, these methods require a pre-defined and biologically relevant optimization criterion, whereas our method is unbiased in that manner and only uses a topology-based decomposition of a network. The framework described in this article could in principle be also extendable to genome-scale networks in the future, e.g. by using network decomposition into tractable sub-models (Hunt et al., 2014) , or via genetic algorithms combined with linear programming solutions (Kaleta et al., 2009) .
